It’s been a decade since the first checkpoint inhibitors were approved, but the problem of low response rates remains in many forms of cancer. Highlight Therapeutics SL, of Valencia, Spain, hopes to change all that with an approach that primes the body to become more responsive to immunotherapies.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer annual meeting, including:: A2, Achilles, Actinium, Actym, Adaptimmune, Adicet, Affimed, Agenus, Anaveon, Apexigen, Aravive, Asher, Aulos, Bicara, Bolt, Candel, Celldex, Cellectis, Celyad, Cero, Checkmate, Codiak, Compugen, Cue, Editas, Elicio, F-star, G1, Grey Wolf.
The Society for Immunotherapy of Cancer meeting, which concludes on Nov. 14, features a wide range of sessions that delve into the most recent advances in tumor immunology and cancer immunotherapy, providing an excellent opportunity for investors and analysts alike to stay up to date on new therapeutics to improve cancer treatments. Overall, data presented at the meeting appears to have been well received, a factor that has helped push up the value of the price weighted BioWorld Cancer index this month.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer’s annual meeting Nov. 9-14, including: Bergenbio, Exuma, Genexine, I-Mab, Imcheck, Innovent, Intensity, Jounce, Nektar, Shattuck, Sotio.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer’s annual meeting Nov. 9-14, including: 4D, Acepodia, Advaxis, Affimed, Agenus, Alkermes, Alx, Amgen, Beam, Bioinvent, Checkpoint, Codiak, Genocea, Huya, Kleo, Oncolytics, Oncosec, Rubius, Transgene, Vigeo, Windmil.
RSS
